Skip to Content

Votrient Side Effects

Generic Name: pazopanib

Note: This document contains side effect information about pazopanib. Some of the dosage forms listed on this page may not apply to the brand name Votrient.

For the Consumer

Applies to pazopanib: oral tablet

Along with its needed effects, pazopanib (the active ingredient contained in Votrient) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking pazopanib:

More common
  • Black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • blurred vision
  • chest pain
  • chills
  • clay colored stools
  • cloudy urine
  • constipation
  • cough
  • coughing up blood
  • dark urine
  • decreased appetite
  • depressed mood
  • difficulty with breathing or swallowing
  • dizziness
  • dry skin and hair
  • feeling cold
  • fever
  • hair loss
  • headache
  • hoarseness or husky voice
  • increased menstrual flow or vaginal bleeding
  • itching, skin rash
  • loss of appetite
  • lower back or side pain
  • muscle cramps and stiffness
  • nausea and vomiting
  • nervousness
  • nosebleeds
  • painful or difficult urination
  • pale skin
  • paralysis
  • pinpoint red spots on the skin
  • pounding in the ears
  • prolonged bleeding from cuts
  • red or black, tarry stools
  • red or dark brown urine
  • redness, swelling, or pain of the skin
  • scaling of the skin on the hands and feet
  • slow or fast heartbeat
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • stomach pain or tenderness
  • swelling of the feet or lower legs
  • swollen glands
  • tingling of the hands and feet
  • ulceration of the skin
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • weight gain
  • yellow eyes or skin
Less common
  • Bleeding from the rectum or bloody stools
  • bloody nose
  • chest discomfort
  • confusion
  • fainting
  • irregular or slow heart rate
  • numbness or tingling in the face, arms, or legs
  • pain or discomfort in the shoulders, arms, jaw, back, or neck
  • sweating
  • swelling or puffiness of the face
  • trouble speaking, thinking, or walking

Some side effects of pazopanib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Change in hair color
  • change in taste
  • decreased weight
  • diarrhea
  • hair loss
  • lack or loss of strength
  • loss of taste
  • thinning of the hair
  • weight loss
Less common
  • Belching
  • heartburn
  • indigestion
  • stomach discomfort, upset, or pain

For Healthcare Professionals

Applies to pazopanib: oral tablet


-ALT and AST elevations occurred early in the treatment course; 92.5% of all transaminase elevations of any grade occurred in the first 18 weeks.
-Hepatic failure was the cause of death for 0.2% of RCC patients and 0.4% of STS patients.[Ref]

Very common (10% or more): Increased ALT (up to 53%), increased AST (up to 53%), increased total bilirubin (up to 36%), increased alkaline phosphatase (up to 32%)
Common (1% to 10%): Abnormal hepatic function, hepatotoxicity, decreased alkaline phosphatase, increased gamma-glutamyltransferase (GGT), abnormal liver function test
Uncommon (0.1% to 1%): Jaundice, drug-induced liver injury, hepatic failure, increased hepatic enzyme
Postmarketing reports: Increased GGT[Ref]


-A majority of the patients with myocardial dysfunction had concurrent hypertension which may have exacerbated cardiac dysfunction in patients at risk possibly by increasing cardiac afterload.
-Cardiac dysfunction included left ventricular dysfunction, cardiac failure, and restrictive cardiomyopathy.
-Venous thromboembolic events included deep vein thrombosis, pulmonary embolism, and thrombosis terms.[Ref]

Very common (10% or more): Hypertension (up to 42%), myocardial dysfunction (up to 11%), chest pain (up to 10%)
Common (1% to 10%): Venous thromboembolic events, cardiac dysfunction, bradycardia, QT prolongation, myocardial infarction or ischemia, hot flush, flushing
Uncommon (0.1% to 1%): Torsades de pointes, congestive heart failure, fatal arterial thromboembolic events, hypertensive crisis[Ref]


Very common (10% or more): Tumor pain (up to 32%), hemorrhagic events (up to 13%)
Common (1% to 10%): Edema, epistaxis, mouth ulceration, dry mouth, mucosal inflammation, gingival infection, hiccups
Uncommon (0.1% to 1%): Fatal hemorrhage, cerebral/intracranial hemorrhage, infections (with or without neutropenia), infectious peritonitis, menorrhagia, metrorrhagia, oropharyngeal pain
Postmarketing reports: Infections (with or without neutropenia)[Ref]

-RCC: The most common hemorrhagic events were hematuria, epistaxis, hemoptysis, and rectal hemorrhage.
-STS: The most common hemorrhagic events were epistaxis, mouth hemorrhage, and anal hemorrhage.
-Edema events included peripheral edema, eye edema, localized edema, and face edema.[Ref]


-TMA included thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).[Ref]

Very common (10% or more): Increased creatinine (up to 26%), proteinuria (up to 12%)
Common (1% to 10%): Increased urea
Uncommon (0.1% to 1%): Nephrotic syndrome, thrombotic microangiopathy (TMA)
Postmarketing reports: Thrombotic microangiopathy (TMA)[Ref]


Very common (10% or more): Diarrhea (up to 59%), nausea (up to 56%), vomiting (up to 33%), gastrointestinal pain (up to 23%), abdominal pain (up to 14%), mucositis (up to 12%), stomatitis (up to 11%)
Common (1% to 10%): Dyspepsia, flatulence, abdominal distension
Uncommon (0.1% to 1%): Perforation or fistula, fatal perforations, hematochezia, melena, frequent bowel movements, hematemesis, pancreatitis, peritonitis
Postmarketing reports: Pancreatitis, flatulence[Ref]

Nervous system

Very common (10% or more): Fatigue (up to 65%), dysgeusia (up to 28%), headache (up to 23%), dizziness (up to 11%)
Common (1% to 10%): Insomnia, dysphonia, lethargy, paresthesia, peripheral sensory neuropathy, chills
Uncommon (0.1% to 1%): Hypoesthesia, somnolence, mucous membrane disorder, cerebral infarction, transient ischemic attack, cerebrovascular accident, ischemic stroke, posterior reversible encephalopathy syndrome/reversible posterior leukoencephalopathy syndrome (PRES/RPLS)
Postmarketing reports: PRES/RPLS[Ref]

-Dysgeusia included ageusia and hypogeusia.[Ref]


Common (1% to 10%): Hypothyroidism, increased thyroid stimulating hormone
Uncommon (0.1% to 1%): Abnormal thyroid function test[Ref]


-Renal cell carcinoma (RCC): The most commonly observed adverse reactions (20% or more) were diarrhea, hypertension, hair color change, nausea, fatigue, anorexia, and vomiting.

-Soft tissue sarcoma (STS): The most commonly observed adverse reactions (20% or more) were fatigue, diarrhea, nausea, decreased weight, hypertension, decreased appetite, vomiting, tumor pain, hair color changes, musculoskeletal pain, headache, dysgeusia, dyspnea, and skin hypopigmentation.[Ref]


Very common (10% or more): Hair color changes (up to 39%), skin hypopigmentation (up to 21%), exfoliative rash (up to 18%), palmar-plantar erythrodysesthesia syndrome (up to 18%), alopecia (up to 12%), rash (up to 11%)
Common (1% to 10%): Dry skin, skin depigmentation, nail disorder, pruritus, erythema, hyperhidrosis
Uncommon (0.1% to 1%): Skin exfoliation, photosensitivity reaction, erythematous rash, skin disorder, macular rash, pruritic rash, vesicular rash, papular rash, skin ulcer[Ref]


Common (1% to 10%): Hematuria[Ref]


Very common (10% or more): Leukopenia (up to 44%), lymphocytopenia (up to 43%), thrombocytopenia (up to 36%), neutropenia (up to 34%), anemia (up to 27%)
Common (1% to 10%): Decreased white blood cell count
Uncommon (0.1% to 1%): Decreased platelet count[Ref]


Very common (10% or more): Decreased weight (up to 48%), increased glucose (up to 45%), decreased appetite (up to 40%), increased albumin (up to 34%), decreased albumin (up to 34%), decreased phosphorus (up to 34%), decreased calcium (up to 33%), decreased sodium (up to 31%), increased potassium (up to 27%), decreased magnesium (up to 26%), anorexia (up to 22%), decreased glucose (up to 17%)
Common (1% to 10%): Increased lipase, increased amylase, dehydration, abnormal blood cholesterol[Ref]


Very common (10% or more): Musculoskeletal pain (up to 23%), myalgia (up to 23%), asthenia (up to 14%)
Common (1% to 10%): Arthralgia, muscle spasms[Ref]


Common (1% to 10%): Blurred vision
Uncommon (0.1% to 1%): Eyelash discoloration


Frequency not reported: Increased toxicity and mortality with other cancer therapies

-Fatal toxicities including pulmonary hemorrhage, gastrointestinal hemorrhage, and sudden death have occurred when used with other cancer agents.


Very common (10% or more): Dyspnea (up to 20%), cough (up to 17%)
Common (1% to 10%): Pneumothorax
Uncommon (0.1% to 1%): Rhinorrhea[Ref]


1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. "Product Information. Votrient (pazopanib)." GlaxoSmithKline, Research Triangle Park, NC.

Some side effects of Votrient may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.